
|Articles|December 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 12
- Volume 16
- Issue 12
ASA404 lung ca trial expanded
ASA404 lung cancer trial expanded
Advertisement
LONDONAntisoma plc announced that its licensing partner Novartis plans to start a pivotal phase III trial of ASA404 in non-small-cell lung cancer in early 2008. This trial has been expanded to include patients with nonsquamous as well as squamous disease, a change that more than doubles the population of NSCLC patients addressed by the trial.
Articles in this issue
over 18 years ago
Third-line single-agent cetuximab ups overall survivalover 18 years ago
Modern multislice CT propels pancreas imaging forwardover 18 years ago
Sorafenib gets ok for liver cancerover 18 years ago
Celgene to acquire Pharmionover 18 years ago
Novacea halts ASCENT-2 trialover 18 years ago
RT/temozolomide raises possibility of cure in glioblastomaover 18 years ago
Brachytherapy as effective in younger as in older menover 18 years ago
MMA not harming patientsover 18 years ago
Kinase inhibitor may prevent RT-induced lung injuryover 18 years ago
FDA approves lower starting dose for dasatinib for CMLNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
2
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
3
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
4
TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)
5


















































